SunPower Corporation (NASDAQ:SPWR) shares moved down -3.09% in last trading session and ended the day at $22.93. SPWR Gross Margin is 20.40% and its has a return on assets of 1.80%. SunPower Corporation (NASDAQ:SPWR) quarterly performance is 5.57%.
On 12 November, SunPower Corp. (NASDAQ:SPWR) announced financial guidance for fiscal year 2016. For fiscal year 2016, the company expects non-GAAP revenue of $3.3 billion to $3.5 billion, gross margin of 13 percent to 15 percent, EBITDA of $515 million to $565 million, capital expenditures of $210 million to $240 million and gigawatts (GW) deployed in the range of 1.7 GW to 2.0 GW. On a GAAP basis, the company expects revenue of $1.2 billion to $1.4 billion, gross margin of 16 percent to 18 percent and net loss of $415 million to $365 million.
8×8 Inc. (NASDAQ:EGHT) ended the last trading day at $11.92. Company weekly volatility is calculated as 4.44% and price to cash ratio as 7.13. 8×8 Inc. (NASDAQ:EGHT) showed a weekly performance of 8.36%.
8×8 (NASDAQ:EGHT) had its price target increased by Craig Hallum from $11.00 to $12.00 in a research report sent to investors on Friday, MarketBeat Ratings reports. Craig Hallum currently has a buy rating on the stock.
On 19 November, Glaukos Corporation (NYSE:GKOS) shares moved down -0.04% and was closed at $25.61. Glaukos Corporation (NYSE:GKOS) year to date (YTD) performance is -17.97%.
Glaukos Corporation (NYSE:GKOS) announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking authorization to study its Travoprost Intraocular Implant with the iDoseTM delivery system for investigational use in the reduction of elevated intraocular pressure (IOP) in patients with glaucoma.
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) shares advanced 6.04% in last trading session and ended the day at $11.41. TTPH has a return on assets of -39.10%. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) quarterly performance is -72.23%.
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), announced that company management gave a corporate presentation, including an update on its eravacycline development program, at the Stifel 2015 Healthcare Conference on November 17, 2015 at 8:00 a.m. Eastern Time at The New York Palace Hotel in New York City.
Boston Scientific Corporation (NYSE:BSX) caters to the Healthcare space. It has a net profit margin of -5.40% and weekly performance is -0.68%. On the last day of trading company shares ended up at $17.62. Boston Scientific Corporation (NYSE:BSX) distance from 50-day simple moving average (SMA50) is 2.13%.
Boston Scientific Corporation (NYSE:BSX) announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device – occurred in Europe following CE mark approval.